Analystreport

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Guggenheim from $26.00 to $18.00.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report